MAPT and Alzheimer disease: Although the feasibility of fluid biomarker tau PET imaging for evaluating the severity of tau pathologies in AD patients still needs to be established by examining their correlation with neuropathological findings in postmortem assessments, the relationship between these two bioassay modalities has been indicated.